0001130889 false true FY 2023 --12-31 true true 0

 449392 502592

 2023-01-01

 2023-06-30

 2024-03-31

 2022-01-01

 2021-12-31

 2021-12-31

 2021-12-31

 2021-12-31

 2022-01-01

 2022-01-01

 2022-01-01

 2023-01-01

 2023-01-01

 2023-01-01

 UNITED STATES

 SECURITIES AND EXCHANGE
COMMISSION

 Washington, D.C. 20549

 FORM

 ANNUAL
 REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the fiscal year ended December 31, 2023

 TRANSITION
 REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the transition period ___ to ___

 Commission file number
 000-32363

 CANCER CAPITAL CORP.

 (Exact name of registrant
as specified in its charter)

 Wyoming

 (State or other jurisdiction of
 incorporation or organization)

 91-1803648

 (I.R.S. Employer Identification
 No.)

 440 East 400 South Ste 300, Salt
 Lake City, Utah

 (Address of principal executive
 offices)

 84111

 (Zip code)

 Issuer's telephone
number, including area code: (801) 323-2395

 Securities registered
pursuant to Section 12(b) of the Act: None

 Securities registered
under Section 12(g) of the Act: Common Stock

if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes No

whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to
such filing requirements for the past 90 days. Yes No

whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files). Yes No

whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller
reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 Large
 accelerated filer

 Non-accelerated filer

 Accelerated
 filer

 Smaller reporting company

 Emerging growth company

 If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 Indicate by checkmark
whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal
control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting
firm that prepared or issued its audit report.

 If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements.

 Indicate by check mark whether any of those error corrections are
restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers
during the relevant recovery period pursuant to §240.10D-1(b).

whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 The registrant did not
have an active trading market for its Common Stock as of the last business day of its most recently completed second fiscal quarter;
therefore, an aggregate market value of shares of voting and non-voting common equity held by non-affiliates cannot be determined.

 The number of shares outstanding
of the registrant's Common Stock as of March 31, 2024 was 6,150,000.

 Documents incorporated
by reference: None

 PART
I

 Item 1.

 Business

 Item 1A.

 Risk Factors

 Item 1B.

 Unresolved Staff Comments

 Item 1C.

 Cybersecurity

 Item 2.

 Properties

 Item 3.

 Legal Proceedings

 Item 4.

 Mine Safety Disclosure

 PART
II

 Item 5.

 Market for Registrant's Common
 Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 Item 6.

 Selected Financial Data

 Item 7.

 Management's Discussion and Analysis of Financial
 Condition and Results of Operations

 Item 8.

 Financial Statements and Supplementary Data

 Item 9.

 Changes in and Disagreements with Accountants on
 Accounting and Financial Disclosure

 Item 9A.

 Controls and Procedures

 Item 9B.

 Other Information

 PART
III

 Item 10.

 Directors, Executive Officers and Corporate
 Governance

 Item 11.

 Executive Compensation

 Item 12.

 Security Ownership of Certain
 Beneficial Owners and Management and Related Stockholder Matters

 Item 13.

 Certain Relationships and Related Transactions,
 and Director Independence

 Item 14.

 Principal Accounting Fees and Services

 PART
IV

 Item 15.

 Exhibits, Financial Statement Schedules

 Signatures

 In this annual report
references to "Cancer Capital," "we," "us," and "our" refer to Cancer Capital Corp.

 FORWARD LOOKING STATEMENTS

 The U.S. Securities and
Exchange Commission ("SEC") encourages companies to disclose forward-looking information so that investors can better understand
future prospects and make informed investment decisions. This report contains these types of statements. Words such as "may,"
"expect," "believe," "anticipate," "estimate," "project," or "continue"
or comparable terminology used in connection with any discussion of future operating Results or financial performance identify forward-looking
statements. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this
report. All forward-looking statements reflect our present expectation of future events and are subject to a number of important factors
and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

 ITEM 1. BUSINESS

 Historical Development

 Cancer Capital Corp. was
incorporated in the state of Nevada on April 11, 1997, to develop an alternative medical waste treatment and processing equipment system.
We were unsuccessful in that endeavor and abandoned that business plan in December 1997. In April 28, 2016, Cancer Capital Corp. filed
Articles of Domestication in the state of Wyoming; effectively moving the Company's state of domicile from Nevada to Wyoming.

 Our Business Plan

 Our business plan is to
seek, investigate, and, if warranted, acquire an interest in a business opportunity. Our acquisition of a business opportunity may be
made by an asset acquisition, merger, exchange of stock, or otherwise. We have very limited sources of capital, and we probably will
only be able to take advantage of one business opportunity.

 Based upon current economic
conditions, management believes that it is possible, if not probable, for a company like ours, without many assets or liabilities, to
negotiate a merger or acquisition with a viable private company. The opportunity arises principally because of the expensive legal and
accounting fees and the length of time associated with the registration process of "going public."

 Our search for a business
opportunity will not be limited to any particular geographical area or industry and includes both U.S. and international companies. Our
management has unrestricted discretion in seeking and participating in a business opportunity, subject to the availability of such opportunities,
economic conditions and other factors. Our management believes companies who desire a public market to enhance liquidity for current
stockholders, or plan to acquire additional assets through issuance of securities rather than for cash, will be potential merger or acquisition
candidates.

 The selection of a business
opportunity in which to participate is complex and extremely risky and will be made by management in the exercise of their business judgment.
Our activities are subject to several significant risks which arise primarily as a result of the fact that we have no operating business
and may acquire or participate in a business opportunity based on the decision of management which will, in all probability, act without
consent, vote, or approval of our stockholders. We cannot assure you that we will be able to identify and merge with or acquire any business
opportunity which will ultimately prove to be beneficial to Cancer Capital and our stockholders. Should a merger or acquisition prove
unsuccessful, it is possible management may decide not to pursue further acquisition activities and management may abandon our search
and we may become dormant or be dissolved.

 It is possible that the
range of business opportunities that might be available for consideration by us could be limited by the fact that while our Common Stock
is cleared for a quotation on the OTC Markets Pink Current Information market, there is currently no public trading of our Common Stock
on any market. We cannot ensure that a market will develop or that a stockholder will be able to liquidate his/her/its investments without
considerable delay, if at all. If a market develops, our shares will likely be subject to the rules of the Securities Enforcement Remedies
and Penny Stock Reform Act of 1990. The liquidity of penny stock is affected by specific disclosure procedures required by those rules
to be followed by all broker-dealers, including but not limited to, determining the suitability of the stock for a particular customer,
and obtaining a written agreement from the customer to purchase the stock. This rule may affect the ability of broker-dealers to sell
our securities and may affect the ability of purchasers to sell our securities in any market.

 Investigation and
Selection of Business Opportunities

 We anticipate that business
opportunities will come to our attention from various sources, including our officers and Directors, our stockholders, professional advisors
such as attorneys and accountants, securities broker-dealers, investment banking firms, venture capitalists, members of the financial
community and others who may present unsolicited proposals. Management expects that prior personal and business relationships may lead
to contacts with these various sources.

 We expect that our due
diligence will encompass, among other things, meetings with the target business's incumbent management and inspection of its facilities,
as necessary, as well as a review of financial and other information which is made available to our management. This due diligence review
may be conducted either by our management or by unaffiliated third parties we may engage. Our limited funds and the lack of full-time
management will likely make it impracticable to conduct a complete and exhaustive investigation and analysis of a target business before
we consummate a business combination. We anticipate that we will rely upon funds provided by advances and/or loans from management and
significant stockholders to conduct investigation and analysis of any potential target companies or businesses. We may also rely upon
the issuance of our Common Stock in lieu of cash payments for services or expenses related to any analysis. Management decisions, therefore,
will likely be made without detailed feasibility studies, independent analysis, market surveys and the like which, if we had more funds
available to us, would be desirable. We will be particularly dependent in making decisions upon information provided by the promoters,
owners, sponsors or other persons associated with the target business seeking our participation.

 Our management will analyze
the business opportunities; however, none of our management are professional business analysts (See Part III, Item 10, below). Our management
has had limited experience with mergers and acquisitions of business opportunities and has not been involved with an initial public offering.
Due to management's limited experience with mergers and acquisitions, they may rely on principal stockholders or associates, or
promoters or their affiliates to assist in the investigation and selection of business opportunities.

 Certain conflicts of interest
exist or may develop between the Company and our officers and Directors. Our management has other business interests to which they currently
devote attention. Our President, Mr. John Peters, holds management positions with another reporting company which is also seeking business
opportunities and Mrs. Michelle Peters is currently employed. (See Part III, Item 10, below.) As a result, conflicts of interest may
arise that can be resolved only through their exercise of judgment in a manner which is consistent with their fiduciary duties to us.

 A decision to participate
in a specific business opportunity may be made upon our management's analysis of:

 •
 the
 quality of the business opportunity's management and personnel,

 •
 the
 anticipated acceptability of its new products or marketing concept,

 •
 the
 merit of its technological changes,

 •
 the
 perceived benefit that it will derive from becoming a publicly held entity, and

 •
 numerous
 other factors which are difficult, if not impossible, to analyze through the application
 of any objective criteria.

 No one factor described
above will be controlling in the selection of a business opportunity. Management will attempt to analyze all factors appropriate to each
opportunity and make a determination based upon reasonable investigative measures and available data. Potential business opportunities
may occur in many different industries and at various stages of development. Thus, the task of comparative investigation and analysis
of such business opportunities will be extremely difficult and complex. Potential investors must recognize that because of our limited
capital available for investigation and management's limited experience in business analysis, we may not discover or adequately
evaluate adverse facts about the business opportunity to be acquired.

 In many instances, we
anticipate that the historical operations of a specific business opportunity may not necessarily be indicative of the potential for the
future operations because of the possible need to substantially shift marketing approaches, significantly expand operations, change product
emphasis, change or substantially augment management, or make other changes. We will be dependent upon the owners of a business opportunity
to identify any such problems which may exist and to implement, or be primarily responsible for, the implementation of required changes.

 Form of Acquisition

 We cannot predict the
manner in which we may participate in a business opportunity. Specific business opportunities will be reviewed as well as our needs and
desires and those of the promoters of the opportunity. The legal structure or method deemed by management to be suitable will be selected
based upon our review and our relative negotiating strength. Such methods may include, but are not limited to, leases, purchase and sale
agreements, licenses, joint ventures and other contractual arrangements. We may act directly or indirectly through an interest in a partnership,
corporation or other forms of organization. We may be required to merge, consolidate or reorganize with other corporations or forms of
business organizations. In addition, our present management and stockholders most likely will not have control of a majority of our voting
shares following a merger or reorganization transaction. As part of such a transaction, our existing Directors may resign and new Directors
may be appointed to fill those vacancies without any vote by our stockholders.

 We likely will acquire
our participation in a business opportunity through the issuance of Common Stock or other securities. Although the terms of any such
transaction cannot be predicted, it should be noted that in certain circumstances the criteria for determining whether or not an acquisition
is a so-called "tax free" reorganization under Section 368(a) (1) of the Internal Revenue Code of 1986, as amended (the "Code")
depends upon whether the owners of the acquired business own 80% or more of the voting stock of the surviving entity. If a transaction
were structured to take advantage of these provisions rather than other "tax free" provisions provided under the Code, all
prior stockholders would in that circumstance retain 20% or less of the total issued and outstanding shares of the surviving entity.
Under other circumstances, depending upon the relative negotiating strength of the parties, prior stockholders may retain substantially
less than 20% of the total issued and outstanding shares of the surviving entity. This could result in substantial additional dilution
to the equity of those persons who were our stockholders prior to such reorganization.

 In the case of an acquisition,
the transaction may be accomplished upon the sole determination of management without any vote or approval by stockholders. In the case
of a statutory merger or consolidation directly involving the Company, it will likely be necessary to call a stockholders' meeting and
obtain the approval of the holders of a majority of the outstanding securities. The necessity to obtain such stockholder approval may
result in delay and additional expense in the consummation of any proposed transaction and will also give rise to certain appraisal rights
to dissenting stockholders. Most likely, management will seek to structure any such transaction so as not to require stockholder approval.

 The time and costs required
to select and evaluate a target business and to structure and complete a business combination cannot presently be ascertained with any
degree of certainty. Any costs incurred with respect to the indemnification and evaluation of a prospective business combination that
is not ultimately completed may result in a loss to the Company. Also, fees may be paid in connection with the completion of all types
of acquisitions, reorganizations or mergers. These fees are usually used to pay legal costs, accounting costs, finder's fees, consultant's
fees and other related expenses. In the event that any such fees are paid, they may become a factor in negotiations regarding any potential
acquisition or merger by us. We have no present arrangements or understandings respecting any of these types of fees.

 Significant stockholders
may actively negotiate or otherwise consent to the purchase of all or any portion of their Common Stock as a condition to, or in connection
with, a proposed reorganization, merger or acquisition. It is not anticipated that any such opportunity will be afforded to other stockholders
or that such other stockholders will be afforded the opportunity to approve or consent to any particular stock buy-out transaction. We
have not adopted any procedures or policies for the review, approval or ratification of any related party transactions.

 In the event we merge
or acquire a business opportunity, the successor company will be subject to our reporting obligations. This is commonly referred to as
a "back door registration." A back door registration occurs when a non-reporting company becomes the successor of a reporting
company by merger, consolidation, exchange of securities, acquisition of assets or otherwise. This type of event requires the successor
company to file a current report with the SEC which provides the same kind of information about the company to be acquired that would
appear in a registration statement, including audited and pro forma financial statements. This regulation may eliminate many of the perceived
advantages of these types of transactions. Accordingly, we may incur additional expense to conduct due diligence and present the required
information for the business opportunity in any report.

 Also, the SEC may elect
to conduct a full review of the successor company and may issue substantive comments on the sufficiency of disclosure related to the
company to be acquired.

 In addition, regulations
also deny the use of Form S-8 for the registration of securities of a shell company, and limit the use of Form S-8 to a reorganized shell
company until the expiration of 60 days from when any such entity is no longer considered to be a shell company. This prohibition could
further restrict opportunities for the Company to acquire companies that may already have stock option plans in place that cover numerous
employees. In such an instance, there may be no exemption from registration for the issuance of securities in any business combination
to these employees, thereby necessitating the filing of a registration statement with the SEC to complete any such reorganization, and
incurring the time and expense costs that are normally avoided by "back door" registrations.

 Competition

 We expect to encounter
substantial competition in our effort to locate attractive business opportunities. Business development companies, venture capital partnerships
and corporations, venture capital affiliates of large industrial and financial companies, small investment companies, and wealthy individuals
will be our primary competition. Many of these entities will have significantly greater experience, resources and managerial capabilities
than we do and will be in a better position than we are to obtain access to attractive business opportunities. We also will experience
competition from other public reporting companies, many of which may have more funds available for such opportunities.

 Effect of Existing
or Probable Governmental Regulations on Business

 We are subject to the
Sarbanes-Oxley Act of 2002. This Act creates a strong and independent accounting oversight board to oversee the conduct of auditors of
public companies and to strengthen auditor independence. It also requires steps to enhance the direct responsibility of senior members
of management for financial reporting and for the quality of financial disclosures made by public companies; establishes clear statutory
rules to limit, and to expose to public view, possible conflicts of interest affecting securities analysts; creates guidelines for audit
committee members' appointment, and compensation and oversight of the work of public companies' auditors; prohibits certain
insider trading during pension fund blackout periods; and establishes a federal crime of securities fraud, among other provisions.

 We are subject to the
Exchange Act of 1934 and are required to file annual reports on Form 10-K and quarterly reports on Form 10-Q with the SEC on a regular
basis, and will be required to timely disclose certain material events (e.g., changes in corporate control; acquisitions or dispositions
of a significant amount of assets other than in the ordinary course of business; and bankruptcy) in a Current Report on Form 8-K. We
are also subject to Section 14(a) of the Exchange Act which requires the Company to comply with the rules and regulations of the SEC
regarding proxy solicitations, as outlined in Regulation 14A. Matters submitted to our stockholders at a special or annual meeting of
stockholders or pursuant to a written consent will require us to provide our stockholders with the information outlined in Schedules
14A or 14C of Regulation 14A; preliminary copies of this information must be submitted to the SEC at least 10 days prior to the date
that definitive copies of this information are forwarded to our stockholders.

 If we acquire a "non-reporting
issuer" under the Exchange Act, we will be subject to the "back-door registration" requirements of the SEC that will
require us to file a Current Report on Form 8-K that will include all information about such "non-reporting issuer" as would
have been required to be filed by that entity had it filed a Form 10 Registration Statement with the SEC.

 Employees

 We currently have no employees.
Our management expects to confer with consultants, attorneys and accountants as necessary. We do not anticipate a need to engage any
full-time employees so long as we are seeking and evaluating business opportunities. We will determine the need for employees based upon
a specific business opportunity, if any.

 Available Information

 We currently do not have
a Company website.

 ITEM 1A. RISK FACTORS

 We are a smaller reporting
company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, we are not required to provide the information
for this Item.

 Item 1B. UNRESOLVED
STAFF COMMENTS.

 We are a smaller reporting
company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, we are not required to provide the information
for this Item.

 Item 1C. Cybersecurity.

 The Company recognizes
the importance of cybersecurity and the potential risks associated with cyber incidents. As a small entity with simple operations managed
solely by our Chief Executive Officer (CEO), we have not implemented formal cybersecurity policies or procedures. However, we take reasonable
steps to protect our electronic data and ensure the security of our operations.

 Given the size of our
company and the nature of our operations, we believe the risk of significant cybersecurity incidents is minimal. Our CEO is responsible
for overseeing all aspects of our business, including the management of cybersecurity risks. We utilize standard commercial software
for business operations, which includes basic security features such as password protection and data encryption.

 To date, we have not experienced
any material cybersecurity incidents, and there has been no known unauthorized access to our systems. We will continue to monitor our
cybersecurity risk profile and take appropriate actions to safeguard our data and systems.

 Should any material cybersecurity
incidents occur, we will assess the situation and disclose the nature, scope, and potential impact of the incident in accordance with
SEC regulations.

 ITEM 2. PROPERTIES

 We do not currently own
or lease any property. Until we pursue a viable business opportunity and recognize income, we will not seek office space.

 ITEM 3. LEGAL PROCEEDINGS

 We are not a party to
any legal proceedings as of the date of this filing.

 ITEM 4. MINE SAFETY
DISCLOSURES

 Not applicable to
our operations.

 ITEM 5. MARKET FOR
REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 Market Information

 Our Common Stock
is listed on the OTC Bulletin Board using the symbol "CNCL." As of the date of this filing there has not been any trading
activity in our Common Stock. Any future over-the-counter market quotations in this trading system reflect inter-dealer prices, without
retail mark-up, mark-downs or commissions, and may not necessarily represent actual transactions.

 Our shares of Common Stock
are subject to Section 15(g) and Rule 15g-9 of the Securities and Exchange Act, commonly referred to as the "penny stock"
rule. The rule defines penny stock to be any equity security that has a market price less than $5.00 per share, subject to certain exceptions.
These rules may restrict the ability of broker-dealers to trade or maintain a market in our Common Stock and may affect the ability of
stockholders to sell their shares. Broker-dealers who sell penny stocks to persons other than established customers and accredited investors
must make a special suitability determination for the purchase of the security. Accredited investors, in general, include individuals
with assets in excess of $1,000,000 (excluding their primary residence) or annual income exceeding $200,000 or $300,000 together with
their spouse, and certain institutional investors. The rules require the broker-dealer to receive the purchaser's written consent
to the transaction prior to the purchase and require the broker-dealer to deliver a risk disclosure document relating to the penny stock
prior to the first transaction. A broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered
representative, and current quotations for the security. Finally, monthly statements must be sent to customers disclosing recent price
information for the penny stocks.

 Holders and Dividends

 We have 38 stockholders
of record holding 6,150,000 common shares as of March 31, 2024. We have not declared dividends on our Common Stock and do not anticipate
paying dividends on our Common Stock in the foreseeable future.

 Recent Sales of
Unregistered Securities

 None.

 Issuer Purchase
of Securities

 None.

 ITEM 6. [Reserved].

 ITEM 7. MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 Executive Overview

 We are an emerging growth
company that has not recorded revenues for the past two fiscal years. We are dependent upon financing to continue basic operations. Management
intends to rely upon advances or loans from management, significant stockholders or third parties to meet our cash requirements, but
we have not entered into written agreements guaranteeing funds and, therefore, no one is obligated to provide funds to us in the future.
These factors raise substantial doubt as to our ability to continue as a going concern. Our plan is to combine with an operating company
to generate revenue.

 If we obtain a business
opportunity, then it may be necessary to raise additional capital. We likely will sell our Common Stock to raise this additional capital.
We anticipate that we would issue such stock pursuant to exemptions to the registration requirements provided by federal and state securities
laws. The purchasers and manner of issuance will be determined according to our financial needs and the available exemptions to the registration
requirements of the Securities Act of 1933. We do not currently intend to make a public offering of our stock. We also note that if we
issue more shares of our Common Stock, then our stockholders may experience dilution in the value per share of their Common Stock.

 Liquidity and Capital
Resources

 We have not recorded revenues
from operations since inception. We have not established an ongoing source of revenue sufficient to cover our operating costs and we
have relied primarily upon related parties to provide and pay for professional and operational expenses.

 At December 31, 2023,
we had cash of $16,157, compared to $22,055 cash at December 31, 2022. The decrease in cash was primarily a result of proceeds from notes
payable of $0 and notes payable related-party of $3,000. At December 31, 2023, total liabilities increased to $465,549, compared to $433,654
at December 31, 2022. This increase in total liabilities primarily represents an increase of notes payable, accrued interest for all
notes payable and the increase of notes payable and notes payable – related party for cash advances, consulting services and professional
services provided by or paid for by third party (See "Commitments and Obligations," below).

 We intend to obtain capital
from management, significant stockholders and/or third parties to cover minimal operations; however, there is no assurance that additional
funding will be available. Our ability to continue as a going concern during the long term is dependent upon our ability to find a suitable
business opportunity and acquire or enter into a merger with such company. The type of business opportunity with which we acquire or
merge will affect our profitability for the long term.

 During the next 12 months
the Company anticipates incurring additional costs related to the filing of Exchange Act reports. We believe we will be able to meet
these costs through advances and loans provided by management, significant stockholders or third parties. We may also rely on the issuance
of our Common Stock in lieu of cash to convert debt or pay for expenses.

 Results of Operations

 We had no revenues during
2023 and 2022. General and administrative expense was $14,897 for 2023, compared to $21,008 for 2022. General and administrative expense
primarily reflects consulting and accounting services relied upon for our operations. Total other expense, representing interest expense
on notes payable and notes payable-related party, increased to $37,792 for 2023, compared to $21,459 for 2022. Accordingly, our net loss
decreased to $37,792 for 2023, compared to $42,467 for 2022. Management expects net losses to continue until we acquire or merge with
a business opportunity.

 Commitments and
Obligations

 At December 31, 2023 and
2022, we had notes payable of $130,275 and $130,275, respectively. The notes bear interest at 8% and are due on demand. Accrued interest
for these notes payable was $74,996 and $64,574 at December 31, 2023 and 2022, respectively.

 Notes payable–related
party at December 31, 2023 and 2022, were $164,125 and $155,125, respectively. The notes bear interest at 8% and are due on demand. Accrued
interest on these notes at December 31, 2023 and 2022, were $90,153 and $77,680, respectively.

 During the years ended
December 31, 2023 and 2022, the Company incurred $6,000 and $6,000, respectively, for consulting, administrative, and professional services
provided by a more than 5% shareholder. In 2023 and 2022, the 2022 and 2021 accounts payable – related party totaling $6,000 were
converted into notes payable – related party.

 As of December 31, 2023
and 2022, two lenders represent in excess of 95% of our accounts payable and notes payable.

 Emerging Growth
Company

 We qualify as an emerging
growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). A company qualifies
as an emerging growth company if it has total annual gross revenues of less than $1.07 billion during its most recently completed fiscal
year and, as of December 8, 2011, had not sold common equity securities under a registration statement. Under the JOBS Act we are permitted
to, and intend to, rely on exemptions from certain disclosure requirements

 In addition, Section
107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section
7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can
delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected
to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those
of companies that comply with such new or revised accounting standards.

 ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA

 CANCER CAPITAL CORP.

 Financial Statements

 December 31, 2023 and 2022

 CONTENTS

 Report of Independent Registered Public Accounting Firm (PCAOB
 ID 6117)

 Report of Independent Registered Public Accounting Firm - Fruci &
 Associates II, PLLC

 Balance Sheets

 Statements of Operations

 Statements of Stockholders' Deficit

 Statements of Cash Flows

 Notes to the Financial Statements

 REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 To the Board of Directors and
Stockholders

 Salt Lake City, Utah

 Opinion on the Financial
Statements

 We have audited the
accompanying balance sheet of Cancer Capital Corp. (the Company) as of December 31, 2022, and the related statements of operations, stockholders'
deficit, and cash flows for the year then ended, and the related notes (collectively referred to as the financial statements). In our
opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31,
2022, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally
accepted in the United States of America.

 Consideration of
the Company's Ability to Continue as a Going Concern

 The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. The Company has suffered recurring losses
and has no operations which raise substantial doubt about its ability to continue as a going concern. Management's plans
in regard to these matters are described in Note 3. The financial statements do not include any adjustments that might result from the
outcome of this uncertainty.

 Basis for Opinion

 These financial statements
are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial
statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We conducted our audit
in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required
to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness
of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 Our audit included
performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for
our opinion.

 /s/ Pinnacle Accountancy Group
of Utah

 We have served as the Company's
auditor since 2017.

 Pinnacle Accountancy Group of
Utah

 Farmington, Utah

 March 24, 2023

 REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM

 To the Board of Directors
and Shareholders of Cancer Capital Corp.

 Opinion on the
Financial Statements

 We have audited
the accompanying balance sheet of Cancer Capital Corp. ("the Company") as of December 31, 2023 and the related statements
of operations, stockholders' deficit, and cash flows for the year ended December 31, 2023, and the related notes (collectively
referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2023 and the results of its operations and its cash flows for the year ended December 31,
2023, in conformity with accounting principles generally accepted in the United States of America.

 Going Concern

 The accompanying
financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial
statements, the Company has limited assets, negative working capital, and net losses since inception. These factors, among others, raise
substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters
are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 Basis for Opinion

 These financial
statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We conducted
our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we
are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 Our audit included
performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for
our opinion.

 Critical Audit
Matters

 Critical audit matters
are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to
the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our
especially challenging, subjective, or complex judgments. We determined that there were no critical audit matters.

 Fruci & Associates II, PLLC –
 PCAOB ID #0 5525

 We have served as the Company's
 auditor since 2023.

 Spokane, Washington

 April
 10, 2024

 Balance Sheets

 DEC
 31, 2023

 DEC
 31, 2022

 ASSETS

 CURRENT
 ASSETS

 Cash

 $

 $

 Total
 current assets

 Total
 assets

 $

 $

 LIABILITIES
 AND STOCKHOLDERS' DEFICIT

 CURRENT
 LIABILITIES

 Accounts
 payable - related party

 $
 6,000

 $
 6,000

 Notes
 payable – related party

 164,125

 155,125

 Notes
 payable

 130,275

 130,275

 Accrued
 interest – related party

 90,153

 77,680

 Accrued
 interest

 74,996

 64,574

 Total
 current liabilities

 465,549

 433,654

 Total
 liabilities

 465,549

 433,654

 Commitments
 and Contingencies

 STOCKHOLDERS'
 DEFICIT

 Common
 stock, $.001 par value; 20,000,000 shares authorized; 6,150,000 shares issued and outstanding

 6,150

 6,150

 Additional
 paid-in capital

 Accumulated
 deficit

 ( 502,592
)

 ( 464,799
)

 Total
 stockholders' deficit

 ( 449,392
)

 ( 411,599
)

 Total
 liabilities and stockholders' deficit

 $

 $

 The accompanying notes are
an integral part of these financial statements.

 Statements of Operations

 FOR THE YEAR ENDED
DEC 31, 2023

 FOR THE YEAR ENDED
DEC 31, 2022

 Revenues

 $
 —

 $
 —

 Operating Expenses

 General and administrative

 14,897

 21,008

 Total operating expenses

 14,897

 21,008

 Loss from operations

 ( 14,897
)

 ( 21,008
)

 Other income (expense)

 Interest expense – related party

 ( 12,473
)

 ( 11,729
)

 Interest expense

 ( 10,422
)

 ( 9,730
)

 Total other income (expense)

 ( 22,895
)

 ( 21,459
)

 Loss before income taxes

)

)

 Income tax expense

 —

 —

 Net loss

 $
)

 $
)

 Net loss per share – basic and diluted

 $
 ( 0.01
)

 $
 ( 0.01
)

 Weighted average shares outstanding – basic and diluted

 The accompanying notes are
an integral part of these financial statements.

 Statements of
Stockholders' Deficit

 For the
years ended December 31, 2023 and 2022

 Additional

 Total

 Common Stock

 Paid-in

 Accumulated

 Stockholders'

 Shares

 Amount

 Capital

 Deficit

 Deficit

 Balance – December 31, 2021

 6,150

 $

 $
 ( 422,332
)

 $
 ( 369,132
)

 Net loss for the year ended December 31, 2022

 —

 —

 —

)

)

 Balance – December 31, 2022

 6,150

 $

 $
 ( 464,799
)

 $
 ( 411,599
)

 Net loss for the year ended December 31, 2023

 —

 —

 —

)

)

 Balance
– December 31, 2023

 6,150

 $

 $
 ( 502,591
)

 $
 ( 449,391
)

 The accompanying notes are
an integral part of these financial statements.

 Statements of Cash Flows

 FOR THE YEAR ENDED
DEC 31, 2023

 FOR THE YEAR ENDED
DEC 31, 2022

 Cash Flows from Operating Activities

 Net Loss

 $
)

 $
)

 Adjustment to reconcile net loss to cash used by operating
 activities:

 Expenses paid by related party

 6,000

 6,000

 Changes in operating assets and liabilities:

 Decrease in accounts payable

 —

 —

 Increase in accrued interest – related party

 12,473

 11,729

 Increase in accrued interest

 10,422

 9,730

 Net cash used by operating activities

 ( 8,897
)

 ( 15,008
)

 Cash Flows from Investing Activities

 Net cash provided by investing activities

 —

 —

 Cash Flows from Financing Activities

 Proceeds from notes payable

 —

 33,000

 Proceeds from notes payable – related party

 3,000

 4,000

 Net cash provided by financing activities

 3,000

 37,000

 Increase (decrease) in cash

 ( 5,897
)

 21,993

 Cash and cash equivalents at beginning of year

 22,054

 Cash and cash equivalents at end of year

 $

 $

 Supplemental Cash Flow Information:

 Cash paid for interest

 $
 —

 $
 —

 Cash paid for income taxes

 $
 —

 $
 —

 Non-Cash Investing and Financing Activities

 Conversion of related party accounts payable into notes payable – related party

 $
 6,000

 $
 6,000

 The accompanying notes are
an integral part of these financial statements.

 Notes to the Financial
Statements

 December 31, 2023 and 2022

 NOTE 1 - SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES

 a. Organization
& Summary of Significant Accounting Policies

 Cancer Capital Corp. (the
Company), was incorporated April 11, 1997 under the laws of the State of Nevada. The Company was originally formed for the purpose of
developing an alternative medical waste treatment system. However, the Company, in December 1997, minimized this purpose and since that
time its efforts have been directed more to raising capital, development of the Company's business plan, SEC filings and other
limited operations.

 b. Loss
Per Share

 The computation of earnings
per share of Common Stock is based on the weighted average number of shares outstanding at the date of the financial statements. There
are no potentially dilutive Common Stock equivalents.

 For the Years Ended
December 31,

 2023

 2022

 Net Loss

 $
)

 $
)

 Weighted Average Number of Shares Outstanding

 Basic Loss per Common Share

 $
 ( 0.01
)

 $
 ( 0.01
)

 c. Cash
and Cash Equivalents

 The Company considers
all highly liquid investments with maturities of three months or less to be cash equivalents.

 d. Use of estimates

 The preparation of financial
statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 e. Concentrations of Risk

 As of December 31, 2023,
two lenders represent in excess of 95 % of the Company's Account Payable and Notes Payable for the fiscal years ended December 31,
2023.

 f. Recent Accounting Pronouncements

 The Company has evaluated
Recent Accounting Pronouncements and has determined that tall such pronouncements either do not apply or their impact is insignificant
to the financial statements.

 g. Fair Value Measurements

 If required by authoritative
literature, the Company would account for certain assets and liabilities at fair value. The cash, accounts payable, notes payable and
accrued interest have fair values that approximate their carrying values due to the short-term nature of these instruments.

 NOTE 2 - INCOME TAXES

 The Company follows
ASC 740-10 which requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination
based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position
to determine the amount to recognize in the financial statements.

 Deferred taxes are provided
on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit
carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences
between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance
when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
 Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 The Company currently
has no issues creating timing differences that would mandate deferred tax expense. Net operating losses would create possible tax assets
in future years. Due to the uncertainty of the utilization of net operating loss carry forwards, a valuation allowance has been made
to the extent of any tax benefit that net operating losses may generate. A provision for income taxes has not been made due to net operating
loss carry-forwards of $ 502,592 and $ 464,799 as of December 31, 2023, and December 31, 2022, respectively, which may be offset against
future taxable income through 2037. No tax benefit has been reported in the financial statements.

 Deferred tax assets and the valuation account
are as follows:

 For the Years Ended
December 31,

 2023

 2022

 Deferred tax asset:

 Net operating loss carryforward (at 21%)

 $
 105,544

 $
 97,608

 Valuation allowance

 ( 105,544
)

 ( 97,608
)

 $
 —

 $
 —

 A reconciliation of amounts
obtained by applying the Federal tax rate to pre-tax income to income tax benefit is as follows:

 For the Years Ended
December 31,

 2023

 2022

 Federal tax benefit (at 21%)

 $
 7,936

 $
 8,918

 Change in valuation allowance

 ( 7,936
)

 ( 8,918
)

 Effect of rate change on Deferred Tax Asset

 —

 —

 $
 —

 $
 —

 The Company did not
have any tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase
or decrease within the next 12 months.

 The Company includes
interest and penalties arising from the underpayment of income taxes in the statements of operations in the provision for income taxes.
 As of December 31, 2023 and 2022, the Company had no accrued interest or penalties related to uncertain tax positions.

 The tax years that
remain subject to examination by major taxing jurisdictions are those for the years ended December 31, 2023, 2022, 2021, and 2020.

 NOTE 3 - GOING CONCERN

 The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has a negative
working capital of $ 449,392 and has incurred losses of $ 502,592 since inception. Its activities
have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial
doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might
result from the outcome of this uncertainty. It is management's plan to acquire or merge with other operating companies.

 NOTE 4 - NOTES PAYABLE

 Notes payable as of December
31, 2023 and 2022 were $ 130,275 and $ 130,275, respectively. The notes bear interest at 8 % and are due on demand. The Company received
proceeds of $ 0 and $ 33,000 during the years ended December 31, 2023 and 2022, respectively.

 Accrued interest for the
notes payable was $ 74,996 and $ 64,574 at December 31, 2023 and 2022, respectively.

 NOTE 5 - RELATED PARTY TRANSACTIONS

 As of the years ended
December 31, 2023 and 2022, the Company incurred $ 6,000 and $ 6,000, respectively, of consulting, administrative, and professional services
to a shareholder. In 2023, the 2022 accounts payable – related party totaling $ 6,000 were converted into notes payable –
related party. In 2022, the 2021 accounts payable – related party totaling $ 6,000 were converted into notes payable – relate
party. Notes payable – related party at December 31, 2023 and 2022, were $ 164,125 and $ 155,125, respectively. Accrued interest
on these notes at December 31, 2023 and 2022, was $ 90,153 and $ 77,680, respectively. The notes bear interest at 8 % and are due on demand.

 NOTE
6 – STOCKHOLDERS' EQUITY

 There was no stock issued during 2023 and 2022.

 NOTE 7
– SUBSEQUENT EVENTS

 The Company has evaluated
subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are
no such events that would have a material impact on the financial statements.

 ITEM 9. CHANGES IN
AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 On November 30, 2023,
the Board of Directors (the "Board") of Cancer Capital Corp. ("Cancer Capital" or the "Company")
agreed to dismiss the Company's independent registered public accounting firm, Pinnacle Accountancy Group of Utah ("Pinnacle"),
effective as of November 30, 2023. Also on November 30, 2023, the Company engaged the accounting firm of Fruci & Associates II, PLLC
as the Company's new independent registered public accounting firm. The Board and the Company's Audit Committee approved
of the dismissal of Pinnacle and the engagement of Fruci & Associates II, PLLC.

 ITEM 9A. CONTROLS AND
PROCEDURES

 Disclosure Controls
and Procedures

 We maintain disclosure
controls and procedures that are designed to ensure that information required to be disclosed in our filings under the Exchange Act is
recorded, processed, summarized and reported within the periods specified in the rules and forms of the SEC. This information is accumulated
to allow timely decisions regarding required disclosure. Our President, who serves as our principal executive officer and principal financial
officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and
he determined that our disclosure controls and procedures were ineffective due to a control deficiency. Specifically, during the period
we did not have additional personnel to allow segregation of duties to ensure the completeness or accuracy of our information. Due to
the size and operations of the Company we are unable to remediate this deficiency until we acquire or merge with another company.

 Management's
Annual Report on Internal Control over Financial Reporting

 Management
is responsible to establish and maintain adequate internal control over financial reporting. Our principal executive officer is responsible
to design or supervise a process that provides reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted accounting principles. The policies and procedures
include

 maintain records in reasonable detail to accurately
and fairly reflect the transactions and dispositions of assets,

 provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles,
and that receipts and expenditures are being made only in accordance with authorizations of management and Directors, and

 provide reasonable assurance regarding prevention
or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.

 For the
year ended December 31, 2023, management has relied on the Committee of Sponsoring Organizations of the Treadway Commission (COSO - 2013),
"Internal Control - Integrated Framework," to evaluate the effectiveness of our internal
control over financial reporting. Based upon that framework, management has determined that our internal control over financial reporting
is ineffective due to the lack of additional personnel to allow segregation of duties to ensure the completeness or accuracy of our information.

 Our management determined
that there were no changes made in our internal controls over financial reporting during the fourth quarter of 202 3
that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

 ITEM 9B. OTHER INFORMATION

 None.

 ITEM 10. DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 Directors and Executive
Officers

 Our Directors and executive
officers and their respective ages, positions, term of office and biographical information are set forth below. Pursuant to our Bylaws,
we have two Directors who serve for terms of one year or until they are replaced by a qualified Director. Our executive officers are
chosen by our Board of Directors and serve at its discretion. John and Michelle Peters are married.

 Name

 Age

 Position Held

 Director Term

 John W. Peters

 Director and President

 From April 1997 until next annual meeting.

 L. Michelle Peters

 Director and Secretary/Treasurer

 From April 1997 until next annual meeting.

 John W. Peters –
 Mr. Peters retired in December 2012 from his employment as an office manager and a manager of a property management company.
Mr. Peters also serves as a Director and executive officer of C & C Tours, Inc., a company that has a class of securities registered
with the SEC pursuant to Section 12.

 Mr. Peters' experience
serving in management positions for private companies and public reporting companies may prove significant in our search for a business
opportunity. Also, his experience with public reporting companies may be critical for our operations moving forward.

 L. Michelle Peters
 – Mrs. Peters is employed with a legal firm as a legal assistant and she has over 40 years of experience working
as a legal assistant and/or paralegal for law firms located in Salt Lake City, Utah and Atlanta, Georgia.

 During the past ten years
none of our executive officers have been involved in any legal proceedings that are material to an evaluation of their ability or integrity;
namely: (1) filed a petition under federal bankruptcy laws or any state insolvency laws, nor had a receiver, fiscal agent or similar
officer appointed by a court for the business or property of such person, or any partnership in which he/she was a general partner at
or within two years before the time of such filing, or any corporation or business association of which he/she was an executive officer
at or within two years before the time of such filing; (2) been convicted in a criminal proceeding or named subject to a pending criminal
proceeding (excluding traffic violations and other minor offenses); (3) been the subject of any order, judgment or decree, not subsequently
reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him/her from or otherwise
limiting his/her involvement in any type of business, securities or banking activities; or (4) been found by a court of competent jurisdiction
in a civil action, by the SEC or the Commodity Futures Trading Commission to have violated any federal or state securities law, and the
judgment in such civil action or finding by the SEC has not been subsequently reversed, suspended, or vacated.

 Code of Ethics

 Since we have only two
persons serving as Directors and executive officers and because we have minimal operations, we have not adopted a code of ethics for
our principal executive and financial officers. Our Board of Directors will revisit this issue in the future to determine if adoption
of a code of ethics is appropriate. In the meantime, our management intends to promote honest and ethical conduct, full and fair disclosure
in our reports to the SEC, and comply with applicable governmental laws and regulations.

 Corporate Governance

 We are a smaller reporting
company with minimal operations and only two Directors and officers. As a result, we do not have a standing nominating committee for
Directors, nor do we have an audit committee with an audit committee financial expert serving on that committee. Our entire Board of
Directors acts as our nominating and audit committee.

 ITEM 11. EXECUTIVE
COMPENSATION

 Executive Officer
Compensation

 Our principal executive
officer, John W. Peters, did not receive compensation from the Company during the year ended December 31, 2023. None of our named executive
officers received any cash or non-cash compensation during the past two fiscal years and none had outstanding equity awards at year end.
We have not entered into employment contracts with our executive officers and their compensation, if any, will be determined at the discretion
of our Board of Directors.

 We do not offer retirement
benefit plans to our executive officers, nor have we entered into any contract, agreement, plan or arrangement, whether written or unwritten,
that provides for payments to a named executive officer at, or in connection with, the resignation, retirement or other termination of
a named executive officer, or a change in control of the company, or a change in the named executive officer's responsibilities
following a change in control.

 Compensation of
Directors

 We do not have any standard
arrangement for compensation of our Directors for any services provided as Director, including services for committee participation or
for special assignments.

 ITEM 12. SECURITY OWNERSHIP
OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 Securities under
Equity Compensation Plans

 None.

 Beneficial Ownership

 The following tables set
forth the beneficial ownership of our outstanding Common Stock of our management and of each person or group known by us to own beneficially
more than 5% of our outstanding Common Stock. Beneficial ownership is determined in accordance with the rules of the SEC and generally
includes voting or investment power with respect to securities. Except as indicated by footnote, the persons named in the table below
have sole voting power and investment power with respect to all shares of Common Stock shown as beneficially owned by them. The percentage
of beneficial ownership is based on 6,150,000 shares of Common Stock outstanding as of March ____, 2024.

 CERTAIN
 BENEFICIAL OWNERS

 Name and address

 of beneficial owner

 Amount and nature

 of beneficial
 ownership

 Percent

 of class

 Compass Equity Partners, LLC

 369 East 900 South, Suite 281

 Salt Lake City, Utah 84111

 500,000

 8.1

 First Equity Holdings Corp.

 2157 S. Lincoln Street

 Salt Lake City, UT 84106

 500,000

 8.1

 MANAGEMENT

 Name of beneficial owner

 Amount and nature

 of beneficial
 ownership

 Percent

 of class

 John W. Peters

 650,000

 10.6

 L.
 Michelle Peters

 450,000

 7.3

 Directors
 and officers as a group

 1,100,000

 17.9

 ITEM 13. CERTAIN RELATIONSHIPS
AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 Transactions with
Related Parties

 The following information
summarizes transactions we have either engaged in for the past two fiscal years or propose to engage in, involving our executive officers,
Directors, more than 5% stockholders, or immediate family members of these persons. These transactions were negotiated between related
parties without "arm's length" bargaining and, as a result, the terms of these transactions may be different than transactions
negotiated between unrelated persons.

 First Equity Holdings
Corp. ("First Equity"), a more than 5% shareholder, paid for consulting, administrative and professional services related
to our business operations valued at $6,000 for 2023, and $6,000 for 2022. At December 31, 2023, the Company owed First Equity $164,125
in notes payable – related party with accrued interest – related party of $90,153. At December 31, 2023, the Company converted
accounts payable – related party for 2022 owed to First Equity of $6,000 to notes payable – related party. At December 31,
2022, the Company owed First Equity $155,125 in notes payable – related party with accrued interest – related party of $65,950.
At December 31, 2022, the Company converted accounts payable – related party for 2021 owed to First Equity of $6,000 to notes payable
– related party.

 Director Independence

 None of our Directors
are independent Directors as defined by NASDAQ Stock Market Rule 5605(a)(2). This rule defines persons as "independent" who
are neither officers nor employees of the company and have no relationships that, in the opinion of the board, would interfere with the
exercise of independent judgment in carrying out their responsibilities as Directors.

 ITEM 14. PRINCIPAL
ACCOUNTING FEES AND SERVICES

 Auditor Fees

 The following table presents
the aggregate fees billed by our principal accounting firm, Fruci & Associates II, PLLC for 2023 audit only and Pinnacle Accountancy
Group of Utah for the 2022 audit and 2023 10-Q reviews.

 Fruci & Associates II, PLLC

 Pinnacle Accountancy Group of Utah

 2023

 2023 /2022

 Audit fees

 $
 6,000

 7,100

 Audit-related fees

 —

 —

 Tax fees

 —

 —

 All other fees

 —

 —

 Total

 $
 6,000

 $
 7,100

 Audit fees represent fees
for professional services rendered by our principal accountants for the audit of our annual financial statements and review of the financial
statements included in our Forms 10-Q or services that are normally provided by our principal accountants in connection with statutory
and regulatory filings or engagements.

 Audit-related fees represent
professional services rendered for assurance and related services by the accounting firm that are reasonably related to the performance
of the audit or review of our financial statements that are not reported under audit fees.

 Tax fees represent professional
services rendered by the accounting firm for tax compliance, tax advice, and tax planning.

 All other fees represent
fees billed for products and services provided by the accounting firm, other than the services reported for the other three categories.

 Pre-approval Policies

 We do not have an audit
committee currently serving and as a result our Board of Directors performs the duties of an audit committee. Our Board of Directors
will evaluate and approve in advance the scope and cost of the engagement of an auditor. All services rendered by our principal accountant
are performed pursuant to a written engagement letter between us and the principal accountant. We do not rely on pre-approval policies
and procedures.

 ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 (a)(1) Financial
Statements

 Financial statements of
Cancer Capital Corp. are included in this report under Item 8 on pages 12 through 20.

 (a)(2) Financial
Statement Schedules

 All financial statement
schedules are included in the footnotes to the financial statements or are inapplicable or not required.

 (a)(3) Exhibits

 The following exhibits
have been filed as part of this report.

 Exhibit No.

 Description

 3(i).1

 Articles of
 Incorporation, dated April 11, 1997 (Incorporated by reference to exhibit 3.1 of the Form 10-SB, File No. 000-32363, filed
 February 20, 2001)

 3(i).2

 Wyoming
 Articles of Domestication for Cancer Capital, dated April 28, 2016 (Incorporated by reference to exhibit 3(i) to Form 10-Q,
 filed May 13, 2016)

 3(ii)

 Bylaws of Cancer Capital, dated May 2,
 2016 (Incorporated by reference to exhibit 3(ii) to Form 10-Q, filed May 13, 2016)

 4.6

 Description
of securities (Incorporated by reference to exhibit 4.6 to Form 10-K, filed April 14, 2020)

 31.1

 Principal Executive Officer
 Certification

 31.2

 Principal Financial Officer
 Certification

 32.1

 Section 1350 Certification

 101.INS

 101.SCH

 101.CAL

 101.DEF

 101.LAB

 101.PRE

 SIGNATURES

 Pursuant to the requirements of Section 13
or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
there unto duly authorized.

 CANCER CAPITAL CORP.

 By: /s/ John W. Peters

 John W. Peters, President

 Date: April 15, 2024

 Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and
on the dates indicated.

 By: /s/ John W. Peters

 John W. Peters

 Director and President

 Principal Executive Officer

 Principal Financial Officer

 Date: April 15, 2024

 By: /s/ L. Michelle Peters

 L. Michelle Peters

 Director and Secretary/Treasurer

 Date: April 15, 2024